BMX-001
Clinical Trials Overview
2 trials found
About BMX-001
BMX-001 is a selective superoxide dismutase mimetic compound designed to function as a radioprotector during radiation therapy for colorectal and other gastrointestinal cancers. The drug works by protecting normal tissues from radiation-induced damage while preserving the therapeutic effects of radiation on tumor cells. Based on clinical trial data, BMX-001 is being evaluated in combination with both short and long course radiation therapy regimens for anal cancer and potentially other colorectal malignancies.
Category
Other Medications
Brand Name
Not yet branded
Mechanism
BMX-001 functions as a synthetic catalyst that mimics the activity of superoxide dismutase, an antioxidant enzyme that neutralizes harmful reactive oxygen species. The compound selectively protects normal tissues by reducing oxidative damage from radiation therapy while maintaining the cytotoxic effects on cancer cells, potentially due to differential uptake or metabolic processing between normal and malignant tissues.
2
Total Trials
1
Recruiting
1
Active
0
Completed
142
Total Enrollment
1
Countries
Active sites for BMX-001
Recruiting sites
1 countries
Phase:
NCT05254327
Phase 2
Recruiting
118 patients
Medications:
BMX-001
In this Phase 2 study, we will conduct an efficacy and safety study of the combination of investigational drug BMX-001, with short-course radiotherapy (SCRT) or long-course chemoradiotherapy (LCCRT) as part of total neoadjuvant therapy in newly diagn...
United States
NCT03386500
Phase 1
Active
24 patients
Medications:
BMX-001
Over 80% of anal cancers are squamous cell carcinoma (SCC). Current standard treatment for locally advanced squamous cell carcinoma of the anal canal is a combination of radiation therapy (RT) and concurrent chemotherapy. This allows for organ preser...
United States